CD28 and neoplasm: Tumor expression of immune checkpoint molecules like PD1, PD-L1 (which binds to PD-1), and CTLA4 (a T-cell immune suppressant that counteracts the stimulatory activity of CD28) are biomarkers of interest to correlate with response to ICI.